Putting The I in Pills
You can bet your bottom dollar that as your eyes scroll over these words there is a room full of pharma executives somewhere thrashing out a strategy towards precision medicine. A topic that was once confined to blue-sky conversations is fast becoming a reality. (Source: EyeForPharma)
Source: EyeForPharma - June 27, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Cross Team Collaboration: The Not So Secret Sauce of Success
Eli Lilly is now several years into just such a transformation, moving from the old advertising and sales model towards integrated and personalized customer engagement.
The aim of the transformation is to serve consumers and health care providers with the right blend of content in the manner of their choosing...Pleaselogin to view the whole article - orsubscribe hereFor a free two week trial to EyeforPharma online, pleaseclick here.Related Content: Cancer Initiative Nets Collaboration AwardMultiple channels or multichannel: In search of digital communications that inspire partnershipsMaking The Digital LeapPrim...
Source: EyeForPharma - June 27, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
In The end, Rare Drug Pricing Will Hurt Pharma Just As Much As Patients
There ’s been an odd-sounding word circulating in the English headlines recently.The word is Orkambi; a drug created by Vertex that treats approximately 40% of people born with the genetic condition, cystic fibrosis. It is the second drug to market in a promising pipeline that targets the CFTR mutation. True gene therapy it isn’t, but it represents a near-first for a biotech firm, by successfully altering the shape and function of a protein[1]. And priced at £105,000 per patient per year, it is the latest in a long line of medicines the NHS can’t afford.Orkambi has been licensed by the EMAsince 2015. It ’s avai...
Source: EyeForPharma - May 24, 2019 Category: Pharmaceuticals Authors: Elly Aylwin-Foster Source Type: news
eyeforpharma awards_nominations open
Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercialImage: URL: https://eloqua.eyeforpharma.com/LP=23914?utm_source=webpage%20tracked%20link%205086&utm_medium=eyeforpharma%20homepageExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - May 15, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Francesco Lucarelli
Company Notes: Francesco Lucarelli joined HCB Health in 2016 and currently serves as managing director of the agency ’s Bio Pharma division. He is responsible for all elements of the division’s work creation, delivery and production; internal team management; and external client development and satisfaction. During his more than 20 years in the pharmaceutical and medical device industries, Francesco has overse en product launches and developed results-driven strategy in a wide variety of leadership roles. He has broad experience in strategic planning and commercialization strategy, client services and business dev...
Source: EyeForPharma - April 9, 2019 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news
Challenging Goliath – How Underdogs Stand A Fighting Chance
We all love an underdog story. Who isn ’t moved by the passion, grit, and determination that drives an outsider to overcome near-impossible odds? Rudy, Rocky, Million Dollar Baby, Miracle – Hollywood has captured our hearts while cashing in on this timeless trope. When it comes to the biopharmaceutical arena, however, we sometimes lo ok down upon the upstart rather than embrace its potential.Smaller companies and products often face the Herculean challenge of going up against the super-power, mega-sized pharma companies. Smaller budgets, operational teams, and fewer sales reps are viewed as insurmountable odds. Some of...
Source: EyeForPharma - March 24, 2019 Category: Pharmaceuticals Authors: Francesco Lucarelli Source Type: news
Catherine Calarco
Company Image: (Source: EyeForPharma)
Source: EyeForPharma - March 6, 2019 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news
